Media

Pulmonx Reports Fourth Quarter and Full Year 2020 Financial Results

Strongbridge Biopharma plc Announces Submission of New Drug Application for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to the U.S. Food & Drug Administration

Fusion Pharmaceuticals To Expand Pipeline With Acquisition Of IPN-1087, A Small Molecule Targeting NTSR1, From Ipsen

Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society’s 2021 Annual Meeting

CARISMA Therapeutics Completes Series B Financing Totaling $59 Million

Nordic Nanovector ASA – Notice of extraordinary general meeting

BONESUPPORT’S FDA NOTIFICATION: APPROVAL ON DENOVO PATHWAY FOR CERAMENT G WILL REQUIRE ADDITIONAL DATA AND CLARIFICATIONS

FDA approves Oncopeptides’ PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma

Year-end report 2020